Panilitian anu dilaporkeun ku panaliti di Fudan University nunjukkeun yén kombinasi anyar opat biomarker protéin tiasa leres ngadiagnosa kanker pancreatic. (Br J Cancer. Vérsi online 9. Nopémber 2017).
The researchers said that we believe that the development of a fast and stable method for screening target proteins in large samples may accelerate the pace of finding new protein biomarkers and drug targets, and may even be individualized in the future. Of proteomes are used in precision medicine.
Lolobana kanker pankréas aya dina tahap maju kasakit dina waktu diagnosis, sarta laju survival median sanggeus diagnosis kirang ti 6%. Diagnosis awal sareng pengobatan tiasa ningkatkeun prognosis.
The researchers used a variety of mass spectrometry techniques to analyze 150 serum samples from healthy controls, patients with benign pancreatic diseases, and patients with pancreatic cancer, and identified 142 differentially expressed proteins. Finally, the four proteins were included in their biomarker expression profiles: APOE , ITIH3, APOA1 and APOL1.
Through the analysis of the area under the curve (AUC) method, the accuracy of a single protein marker used to distinguish pancreatic cancer patients from healthy controls was between 66.9% and 89.6%. The combination of the four markers can increase the accuracy to 93.7%. The sensitivity of the four-protein biomarker combination in the diagnosis of pancreatic cancer was 85%, and the specificity was 94.1%. If CA19-9 is included in this detection method, the AUC will be increased to 0.99, at which time the sensitivity is 95% and the specificity is 94.1%.
Para panaliti ogé ngagunakeun imunohistokimia pikeun ngonfirmasi éksprési spidol protéin di luhur dina sampel tumor, salajengna ngaverifikasi reliabilitas kombinasi biomarker anyar ieu.
Panaliti nyarios yén aplikasi klinis biomarker ieu masih ngagaduhan jalan anu panjang. US FDA nembé ngan ukur nyatujuan kombinasi spidol uji analisis tumor ti Pusat Kanker Peringatan Sloan Kettering anu disebut IMPACT. IMPACT tiasa gancang mendakan mutasi dina 468 gén sareng parobahan molekul sanés dina komposisi génom tumor manusa.
